490 reports of this reaction
3.7% of all TRAVOPROST reports
#3 most reported adverse reaction
OCULAR HYPERAEMIA is the #3 most commonly reported adverse reaction for TRAVOPROST, manufactured by Novartis Pharmaceuticals Corporation. There are 490 FDA adverse event reports linking TRAVOPROST to OCULAR HYPERAEMIA. This represents approximately 3.7% of all 13,183 adverse event reports for this drug.
Patients taking TRAVOPROST who experience ocular hyperaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OCULAR HYPERAEMIA is moderately reported among TRAVOPROST users, representing a notable but not dominant share of adverse events.
In addition to ocular hyperaemia, the following adverse reactions have been reported for TRAVOPROST:
The following drugs have also been linked to ocular hyperaemia in FDA adverse event reports:
OCULAR HYPERAEMIA has been reported as an adverse event in 490 FDA reports for TRAVOPROST. This does not prove causation, but indicates an association observed in post-market surveillance data.
OCULAR HYPERAEMIA accounts for approximately 3.7% of all adverse event reports for TRAVOPROST, making it one of the most commonly reported side effect.
If you experience ocular hyperaemia while taking TRAVOPROST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.